Table 1. Clinicopathological characteristics of PDAC patients enrolled in the study (n=45).
| Parameter | |
|---|---|
| Age, years (median (range)) | 70 (38–87) |
| Sex, n (%) | |
| Male | 29 (64.4) |
| Female | 16 (35.6) |
| Diabetes mellitus, n (%) | 14 (31.1) |
| Family cancer history, n (%) | 17 (37.8) |
| NACRT, n (%) | |
| Performed | 11 (24.4) |
| Not performed | 34 (75.6) |
| Surgery, n (%) | |
| Pancreaticoduodenectomy | 25 (55.6) |
| Distal pancreatectomy | 16 (35.6) |
| Total pancreatectomy | 4 (8.9) |
| Pathological stage (UICC), n (%) | |
| IA | 2 (4.4) |
| IB | 0 (0.0) |
| IIA | 8 (17.8) |
| IIB | 35 (77.8) |
| III | 0 (0.0) |
| IV | 0 (0.0) |
| Resection status, n (%) | |
| R0 | 36 (80.0) |
| R1 | 9 (20.0) |
| Perioperative chemotherapy, n (%) | |
| PI | 32 (71.1) |
| Adjuvant chemotherapy, n (%) | |
| S-1 or GEM | 37 (82.2) |
| Postoperative hospital stay, days (median±s.d.) | 29±9.47 |
Abbreviations: GEM=gemcitabine; NACRT=neo-adjuvant chemoradiotherapy; PDAC=pancreatic ductal adenocarcinoma; PI=portal infusion; s.d.=standard deviation; UICC=Union for International Cancer Control.